MA43532A - Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques - Google Patents

Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques

Info

Publication number
MA43532A
MA43532A MA043532A MA43532A MA43532A MA 43532 A MA43532 A MA 43532A MA 043532 A MA043532 A MA 043532A MA 43532 A MA43532 A MA 43532A MA 43532 A MA43532 A MA 43532A
Authority
MA
Morocco
Prior art keywords
compositions
treatment
methods
disorders related
epileptic seizures
Prior art date
Application number
MA043532A
Other languages
English (en)
Inventor
David Chernoff
Timothy J Fultz
Sangita Ghosh
Jack Nguyen
Gregory T Went
Original Assignee
Adamas Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adamas Pharmaceuticals Inc filed Critical Adamas Pharmaceuticals Inc
Publication of MA43532A publication Critical patent/MA43532A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA043532A 2015-12-30 2016-12-30 Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques MA43532A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562273187P 2015-12-30 2015-12-30

Publications (1)

Publication Number Publication Date
MA43532A true MA43532A (fr) 2018-11-07

Family

ID=57838557

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043532A MA43532A (fr) 2015-12-30 2016-12-30 Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques

Country Status (11)

Country Link
US (3) US10973783B2 (fr)
EP (1) EP3397253A1 (fr)
JP (2) JP6902033B2 (fr)
CN (1) CN109069480A (fr)
AU (1) AU2016381366A1 (fr)
BR (1) BR112018012870A2 (fr)
CA (1) CA3008170A1 (fr)
IL (1) IL259861A (fr)
MA (1) MA43532A (fr)
MX (1) MX2018008021A (fr)
WO (1) WO2017117569A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
JP6902033B2 (ja) 2015-12-30 2021-07-14 アダマス ファーマシューティカルズ， インコーポレイテッド 発作−関連障害の処置のための方法および組成物
CN109255370B (zh) * 2018-08-20 2021-07-27 安徽大学 一种基于pauc算法的农田智能喷药方法
CA3115235A1 (fr) * 2018-10-03 2020-04-09 Cavion, Inc. Traitement des tremblements essentiels a l'aide de (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
US12042474B2 (en) 2019-06-06 2024-07-23 Shanghai Aucta Pharmaceuticals Co., Ltd. Lacosamide pharmaceutical composition and dosage form thereof
EP3981390A4 (fr) * 2019-06-06 2023-01-25 Shanghai Aucta Pharmaceuticals Co., Ltd. Composition pharmaceutique de lacosamide et sa préparation pharmaceutique
CN111407738A (zh) * 2020-04-03 2020-07-14 江苏艾立康药业股份有限公司 一种布立西坦控释制剂及其制备方法
EP3964201A4 (fr) * 2020-07-09 2022-12-28 Shanghai Bocimed Pharmaceutical Co., Ltd. Composition pharmaceutique de brivaracétam, son procédé de préparation et application associée
CN113244197B (zh) * 2021-05-24 2023-02-28 天方药业有限公司 一种卡马西平缓释胶囊剂及其制备方法
CN115343386B (zh) * 2022-07-25 2024-09-17 南京海纳医药科技股份有限公司 一种hplc-ms/ms联用检测人血浆中吡仑帕奈的方法
CN115326960B (zh) * 2022-08-11 2024-03-15 复旦大学附属华山医院 一种同时检测人血浆中8种抗癫痫药物及1种活性代谢物浓度的分析方法

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH500196A (de) 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
US4988731A (en) 1979-08-20 1991-01-29 Abbott Laboratories Sodium hydrogen divalproate oligomer
US5212326A (en) 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
WO1995013796A1 (fr) 1993-11-16 1995-05-26 Depotech Corporation Vesicules a taux controle de liberation des principes actifs
GB8412357D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
US5378729A (en) 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5654301A (en) 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
IT1237904B (it) 1989-12-14 1993-06-18 Ubaldo Conte Compresse a rilascio a velocita' controllata delle sostanze attive
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5221536A (en) 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5326570A (en) 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
KR100221695B1 (ko) 1991-08-12 1999-09-15 그린 마틴, 브라이언 쥐 테슬리 약학적 구상 제형
US5358721A (en) 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
ZA953078B (en) 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
US5773475A (en) 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US20020022056A1 (en) 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
US6048899A (en) 1997-03-17 2000-04-11 Research Corporation Tech., Inc. Anticonvulsant enantiomeric amino acid derivatives
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
ES2172944T3 (es) 1997-12-05 2002-10-01 Alza Corp Forma de dosificacion osmotica que comprende un primer y un segundo revestimiento.
US6107492A (en) 1998-05-08 2000-08-22 Ucb, S.A. Process for the preparation of levetiracetam
CN1161101C (zh) 1998-12-17 2004-08-11 阿尔扎有限公司 用多层包衣将填充液体的明胶胶囊转变成控制释放的系统
US6528090B2 (en) 1998-12-18 2003-03-04 Abbott Laboratories Controlled release formulation of divalproex sodium
US6713086B2 (en) 1998-12-18 2004-03-30 Abbott Laboratories Controlled release formulation of divalproex sodium
US6511678B2 (en) 1998-12-18 2003-01-28 Abbott Laboratories Controlled release formulation of divalproex sodium
GB9930058D0 (en) 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
GB0004297D0 (en) 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
WO2004002565A1 (fr) 2002-06-26 2004-01-08 Alza Corporation Piston peu flexible efficace d'un point de vue volumique pour systemes d'administration de medicaments osmotiques
US6913768B2 (en) 2002-09-24 2005-07-05 Shire Laboratories, Inc. Sustained release delivery of amphetamine salts
EP1579858A1 (fr) 2004-03-26 2005-09-28 Schwarz Pharma Ag Nouvelle utilisation de peptides pour le traitement de la neuropathie diabètique
US20070042969A1 (en) 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
CA2565154A1 (fr) 2004-05-03 2005-11-24 Duke University Compositions influant sur la perte de poids
EP1604655A1 (fr) 2004-06-09 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement de neuralgies trigeminales
EP1604656A1 (fr) 2004-06-09 2005-12-14 Schwarz Pharma Ag Utilisation nouvelle de peptides pour le traitement de la sclérose amytrophique latérale (ALS)
WO2006036007A2 (fr) 2004-09-30 2006-04-06 Takeda Pharmaceutical Company Limited Preparation a liberation modifiee
JP2006124385A (ja) 2004-09-30 2006-05-18 Takeda Chem Ind Ltd 放出制御製剤
EP1642889A1 (fr) 2004-10-02 2006-04-05 Schwarz Pharma Ag Route de synthèse améliorée pour lacosamide
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006058236A2 (fr) 2004-11-24 2006-06-01 Neuromolecular Pharmaceuticals, Inc. Composition et methode pour traiter des affections neurologiques
US20060165745A1 (en) 2005-01-21 2006-07-27 Yiwen Chew Sustained release tablets for treatment of aqueous environment and methods for making the same
DE05815688T1 (de) 2005-01-27 2008-06-26 Alembic Ltd. Levetiracetam-formulierung mit verlängerter freisetzung
CA2604052C (fr) 2005-04-06 2014-07-08 Adamas Pharmaceuticals, Inc. Methode et compositions de traitement des affections du snc
US20070071819A1 (en) 2005-05-30 2007-03-29 Kesarwani Amit K Multiple unit modified release compositions of carbamazepine and process for their preparation
EP1731149A1 (fr) 2005-06-08 2006-12-13 Ucb S.A. Utilisation de Brivaracetam pour le traitement de maladies caracterisées par l'épilepsie myoclonique progressive
US20070048372A1 (en) 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (fr) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) pour le traitement de la myalgie, par exemple de la fibromyalgie
US20070043120A1 (en) 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
WO2007120485A2 (fr) 2006-03-30 2007-10-25 Cinergen, Llc Procédés de traitement de la douleur avec des alkylxanthines et des antiépileptiques et compositions à utiliser à cet effet
EP1873527A1 (fr) 2006-06-30 2008-01-02 Schwarz Pharma Ag Procédé d'identification des modulateurs CRMP
KR20150003925A (ko) 2006-06-15 2015-01-09 유씨비 파르마 게엠베하 상승적 항경련 효과를 갖는 약제학적 조성물
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
JP2010515754A (ja) 2007-01-11 2010-05-13 ゼノポート，インコーポレイティド Ｒ−バクロフェンのプロドラッグの徐放性経口剤形及び治療方法
US7981930B2 (en) 2007-03-13 2011-07-19 Adamas Pharmaceuticals, Inc. Compositions and kits for treating influenza
EP2214657A1 (fr) 2007-10-23 2010-08-11 UCB Pharma GmbH Composés pour le traitement de conditions de démyélinisation
AU2009221177B2 (en) 2008-03-03 2013-05-30 Ucb Biopharma Sprl Pharmaceutical solutions, process of preparation and therapeutic uses
WO2009146325A1 (fr) 2008-05-28 2009-12-03 Pliva Hrvatska D.O.O. Formes polymorphes et amorphes de lacosamide et compositions amorphes
DK2285357T3 (da) 2008-05-30 2014-06-02 Ucb Pharma Sa Farmaceutisk sammensætning omfattende brivaracetam
US20100120906A1 (en) 2008-07-18 2010-05-13 Valeant Pharmaceuticals International Modified release formulation and methods of use
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
BRPI0920342A2 (pt) 2008-10-16 2020-06-23 The Johns Hopkins University Uso de um inibidor da proteína vesicular sináptica 2a (sv2a) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica para melhora da função cognitiva, uso de levitiracetam ou um sal farmaceuticamente aceitável do mesmo, uso de brivaracetam ou um sal farmaceuticamente aceitável do mesmo, uso do seletracetam ou um sal farmaceuticamente aceitável do mesmo
AU2009317279B2 (en) 2008-11-18 2013-10-24 Ucb Pharma, S.A. Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate
EA019572B1 (ru) 2008-11-18 2014-04-30 Юсб Фарма, С.А. Фармацевтические пероральные композиции с пролонгированным высвобождением, включающие производные 2-оксо-1-пирролидина
DE102008059155A1 (de) 2008-11-27 2010-06-02 Ratiopharm Gmbh Trockenverarbeitung und neue Formen von Lacosamid
GB2467312B (en) * 2009-01-28 2013-06-26 Mark Labudek Design Ltd Titanium alloy, a method of producing the alloy and an article made of the alloy
JP5576401B2 (ja) 2009-01-29 2014-08-20 ユセベ ファルマ ソシエテ アノニム ２−オキソ−１−ピロリジン誘導体を含む医薬組成物
DK2391351T3 (da) 2009-01-29 2014-12-01 Ucb Pharma Sa Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater
US8563036B2 (en) 2009-02-09 2013-10-22 Ucb Pharma, S.A. Pharmaceutical compositions comprising Brivaracetam
WO2011015617A1 (fr) 2009-08-06 2011-02-10 Medichem, S.A. Formes solides d'un dérivé de n-(phénylméthyl)propanamide et leurs procédés de préparation
US10786464B2 (en) 2009-11-03 2020-09-29 Lupin Limited Modified release formulation of lacosamide
MX365650B (es) 2009-12-02 2019-06-10 Adamas Pharmaceuticals Inc Composiciones de amantadina y metodos para su uso.
WO2011101863A2 (fr) 2010-02-19 2011-08-25 Cadila Healthcare Limited Compositions pharmaceutiques à libération prolongée de lacosamide
US20130039957A1 (en) 2010-04-29 2013-02-14 Lupin Limited Controlled release pharmaceutical compositions of brivaracetam
CA2817654A1 (fr) 2010-12-02 2012-06-07 Ucb Pharma Gmbh Formulation de lacosamide en prise quotidienne unique
EP2468261A1 (fr) * 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation de lacosamide
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
CA2846503A1 (fr) 2011-09-07 2013-03-14 Novartis Ag Utilisation de 1h-quinazoline-2, 4-diones dans la prevention ou le traitement de l'epilepsie photosensible
KR101732731B1 (ko) 2013-04-02 2017-05-08 주식회사 바이오파마티스 라코사마이드(lacosamide) 또는 이의 약학적으로 허용 가능한 염의 용출 패턴 조절이 용이한 약학 조성물
EP2801350B1 (fr) 2013-05-08 2018-08-01 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations pharmaceutiques de lacosamide
EP2801352B1 (fr) 2013-05-08 2017-07-05 Sanovel Ilac Sanayi ve Ticaret A.S. Formulation à désintégration orale de lacosamide
WO2014180912A1 (fr) 2013-05-08 2014-11-13 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulations à libération modifiée de lacosamide
US20170035733A1 (en) 2013-11-29 2017-02-09 Ucb Pharma Gmbh Pharmaceutical composition comprising lacosamide and levetiracetam
JP6902033B2 (ja) 2015-12-30 2021-07-14 アダマス ファーマシューティカルズ， インコーポレイテッド 発作−関連障害の処置のための方法および組成物

Also Published As

Publication number Publication date
AU2016381366A1 (en) 2018-06-28
JP2019500353A (ja) 2019-01-10
US20170189342A1 (en) 2017-07-06
US20220062204A1 (en) 2022-03-03
EP3397253A1 (fr) 2018-11-07
BR112018012870A2 (pt) 2018-12-04
WO2017117569A1 (fr) 2017-07-06
US20180161282A1 (en) 2018-06-14
CN109069480A (zh) 2018-12-21
JP6902033B2 (ja) 2021-07-14
US10973783B2 (en) 2021-04-13
JP2021095418A (ja) 2021-06-24
IL259861A (en) 2018-07-31
US10987324B2 (en) 2021-04-27
MX2018008021A (es) 2018-11-09
CA3008170A1 (fr) 2017-07-06

Similar Documents

Publication Publication Date Title
MA43532A (fr) Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques
IL304429A (en) Methods and preparations for the treatment of epileptic disorders
DK3185876T3 (da) Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser
FR3046933B1 (fr) Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
DK3261640T3 (da) 5ht-agonister til behandling af epilepsilidelser
MA46365A (fr) Méthodes de traitement de troubles mitochondriaux et métaboliques
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
IL255109A0 (en) New dihydropyridoisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
MA41119A (fr) Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
DK2877184T3 (da) Sammensætninger og behandling for øjensygdomme og -lidelser
DK3102213T3 (da) Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser
DK2747763T3 (da) (bacterio-)chlorofyllfotosensibilisatorer til behandling af øjensygdomme og -lidelser
DK3485890T3 (da) Sglt2-hæmmere til behandling af stofskifteforstyrrelser hos hundedyr
MA42953A (fr) Composés et compositions pour le traitement de troubles oculaires
MA47212A (fr) Méthodes de traitement de troubles neurologiques
GB201411241D0 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MA42999A (fr) Polythérapie pour le traitement de malignités
GB201401086D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
MA39927A (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
DK3256466T3 (da) 1-heterocyclyl-isochromanylforbindelser og analoger til behandling af cns-forstyrrelser
DK3515455T3 (da) Forbindelser til behandling af lidelser i lipoproteinmetabolismen
FR3034011B1 (fr) Procede de traitement cosmetique des cheveux
MA47595A (fr) Méthodes de traitement d'affections neurodégénératives
DK3365329T3 (da) Nurr1:rxr aktiverende forbindelser til samtidig behandling af symptomer og patologi for parkinsons sygge
DK3200828T3 (da) Intranasale sammensætninger til behandling af neurologiske og neurodegenerative sygdomme og forstyrrelser